Home › Compare › XINXF vs ABBV
XINXF yields 1.51% · ABBV yields 3.06%● Live data
📍 XINXF pulled ahead of the other in Year 5
Combined, XINXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XINXF + ABBV for your $10,000?
New Work SE operates professional networking platforms in Germany and internationally. It operates through B2C, B2B E-Recruiting, and B2B Marketing Solutions & Events segments. The B2C segment serves XING members who use xing.com, XING Jobs, and kununu.com or internations.org to network with other professionals for finding a suitable job, obtaining information about employers, or reading about career-related topics. The B2B E-Recruiting segment products portfolio includes Job ads (XJM), XING TalentManager (XTM), XING TalentPoolManager (XTP), XING Talent Referral Manager (XRM), Employee branding profile, Prescreen Applicant Tracking System, XING TalentService (XTS), XING 360 package, and Honeypot. This segment serves customers who seek access to employees and talent. The B2B Marketing Solutions & Events segment offers native, video, and content advertising formats, sponsored mailings, audience network, and event subsegment, as well as ticketing solutions. This segment serves advertising and events clients. The company was formerly known as Xing SE and changed its name to New Work SE in August 2019. The company was founded in 2003 and is based in Hamburg, Germany. New Work SE is a subsidiary of Burda Digital SE.
Full XINXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.